MDACC Study No:2004-0983 ( NCT No: NCT00338039)
Title:Phase II trial of induction cetuximab (IM-C225) gemcitabine and oxaliplatin, followed by radiotherapy with concurrent capecitabine, and cetuximab, followed by maintenance cetuximab and gemcitabine for patients with locally advanced pancreatic cancer
Principal Investigator:Christopher H. Crane
Treatment Agent:Capecitabine; Cetuximab; Gemcitabine; Oxaliplatin; Radiation
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if the drug cetuximab
(C225, ErbituxTM) combined with chemotherapy (gemcitabine and oxaliplatin)
followed by radiation therapy given with chemotherapy (capecitabine) and
cetuximab will help to control pancreatic cancer. The safety of this
combination treatment will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Gastrointestinal
Phase of Study:Phase II
Treatment Agents:Capecitabine
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Patient will be seen on a weekly basis. Patient will been seen every 2 weeks
during induction and maintenance phases during chemoradiation.
Home Care:All treatment must be given at MDACC.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Christopher H. Crane
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-2300
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults